{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:40:10Z","timestamp":1792644010224,"version":"4.5.0"},"reference-count":200,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFF1204905"],"award-info":[{"award-number":["2023YFF1204905"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U25A20123"],"award-info":[{"award-number":["U25A20123"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119340","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T07:02:01Z","timestamp":1790319721000},"page":"119340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting PIM kinases in cancer and inflammatory disorders: From mechanisms to clinical translation"],"prefix":"10.1016","volume":"320","author":[{"given":"Qingyan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8809-7896","authenticated-orcid":false,"given":"Lin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9388-2887","authenticated-orcid":false,"given":"Liping","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8076-163X","authenticated-orcid":false,"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc2986","article-title":"For better or for worse: the role of pim oncogenes in tumorigenesis","volume":"11","author":"Nawijn","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.ejmech.2026.119340_bib2","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/j.1460-2075.1985.tb03852.x","article-title":"Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas","volume":"4","author":"Selten","year":"1985","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2026.119340_bib3","article-title":"PIM1 signaling in immunoinflammatory diseases: an emerging therapeutic target","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119340_bib4","first-page":"4085","article-title":"The role of pim kinase in immunomodulation","volume":"10","author":"Liu","year":"2020","journal-title":"Am. J. Cancer Res."},{"issue":"Pt 1","key":"10.1016\/j.ejmech.2026.119340_bib5","article-title":"A review on structure-function mechanism and signaling pathway of serine\/threonine protein PIM kinases as a therapeutic target","volume":"270","author":"Rout","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/med.21284","article-title":"The PIM family of serine\/threonine kinases in cancer","volume":"34","author":"Narlik-Grassow","year":"2014","journal-title":"Med. Res. Rev."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119340_bib7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/cancers16030535","article-title":"PIM3 kinase: a promising novel target in solid cancers","volume":"16","author":"Ozpolat","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119340_bib8","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3324\/haematol.2009.017079","article-title":"PIM serine\/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers","volume":"95","author":"Brault","year":"2010","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.ejmech.2026.119340_bib9","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1182\/blood-2003-09-3126","article-title":"Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3","volume":"103","author":"Peltola","year":"2004","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119340_bib10","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/1535-7163.MCT-18-0374","article-title":"Mechanisms behind resistance to PI3K inhibitor treatment induced by the PIM kinase","volume":"17","author":"Song","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119340_bib11","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.apsb.2022.12.001","article-title":"A novel IRAK4\/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR\/MYD88-mediated NF-\u03baB pathway","volume":"13","author":"Yoon","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"22","key":"10.1016\/j.ejmech.2026.119340_bib12","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.3390\/cells11223700","article-title":"Targeting PIM kinases to improve the efficacy of immunotherapy","volume":"11","author":"Clements","year":"2022","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.ejmech.2026.119340_bib13","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.41744","article-title":"Pim kinases as therapeutic targets in early rheumatoid arthritis","volume":"73","author":"Maney","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119340_bib14","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/art.40863","article-title":"Pim-1 as a therapeutic target in lupus nephritis","volume":"71","author":"Fu","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119340_bib15","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1007\/s10620-012-2106-7","article-title":"Inhibition of Pim-1 kinase ameliorates dextran sodium sulfate-induced colitis in mice","volume":"57","author":"Shen","year":"2012","journal-title":"Dig. Dis. Sci."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119340_bib16","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41416-018-0082-1","article-title":"Phase I studies of AZD1208, a proviral integration moloney virus kinase inhibitor in solid and haematological cancers","volume":"118","author":"Cortes","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119340_bib17","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1038\/s41375-019-0482-0","article-title":"The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed And\/or refractory multiple myeloma","volume":"33","author":"Raab","year":"2019","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2026.119340_bib18","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1182\/blood-2024-200268","article-title":"A phase 1\/2 Study of nuvisertib (TP-3654), an investigational selective PIM1 kinase inhibitor, in combination with JAK inhibitors ruxolitinib or momelotinib in patients with myelofibrosis","volume":"144","author":"Mascarenhas","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ejmech.2026.119340_bib19","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.clml.2023.05.002","article-title":"Phase 1\/2 study of the Pan-PIM kinase inhibitor INCB053914 alone or in combination with standard-of-care agents in patients with advanced hematologic malignancies","volume":"23","author":"Patel","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib20","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/1078-0432.CCR-17-1629","article-title":"Concurrent inhibition of pim and FLT3 kinases enhances apoptosis of FLT3-ITD acute myeloid leukemia cells through increased Mcl-1 proteasomal degradation","volume":"24","author":"Kapoor","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.ejmech.2026.119340_bib21","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/bloodadvances.2019000260","article-title":"The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN","volume":"3","author":"Mazzacurati","year":"2019","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s43856-024-00444-8","article-title":"S100A8\/A9 predicts response to PIM kinase and PD-1\/PD-L1 inhibition in triple-negative breast cancer mouse models","volume":"4","author":"Begg","year":"2024","journal-title":"Commun. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119340_bib23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.chembiol.2023.10.023","article-title":"PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer","volume":"31","author":"Torres-Ayuso","year":"2024","journal-title":"Cell Chem. Biol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119340_bib24","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1074\/jbc.M409123200","article-title":"Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase","volume":"280","author":"Qian","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.ejmech.2026.119340_bib25","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1021\/jm0504858","article-title":"Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase","volume":"48","author":"Bullock","year":"2005","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100178","article-title":"Dual FLT3\/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1\/2 DIAMOND-01 trial","volume":"3","author":"Martinelli","year":"2026","journal-title":"Blood Neoplasia"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/ajh.27513","article-title":"High-grade B-cell lymphoma not otherwise specified, with diffuse large B-cell lymphoma gene expression signatures: genomic analysis and potential therapeutics","volume":"100","author":"Lone","year":"2025","journal-title":"Am. J. Hematol."},{"issue":"35","key":"10.1016\/j.ejmech.2026.119340_bib28","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.2174\/138161210794454996","article-title":"Using insights into Pim1 structure to design new anticancer drugs","volume":"16","author":"Schenone","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2026.119340_bib29","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-014-0095-z","article-title":"Pim kinases in hematological malignancies: where are we now and where are we going?","volume":"7","author":"Mondello","year":"2014","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119340_bib30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/j.1460-2075.1991.tb07994.x","article-title":"The pim-1 oncogene encodes two related protein-serine\/threonine kinases by alternative initiation at AUG and CUG","volume":"10","author":"Saris","year":"1991","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119340_bib31","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1074\/jbc.M707773200","article-title":"The 44-kDa Pim-1 kinase phosphorylates BCRP\/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells","volume":"283","author":"Xie","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119340_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117866","article-title":"A serine\/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy","volume":"255","author":"Panchal","year":"2020","journal-title":"Life Sci."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119340_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007112","article-title":"Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor","volume":"4","author":"Bullock","year":"2009","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119340_bib34","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150217","article-title":"Control of Pim2 kinase stability and expression in transformed human haematopoietic cells","volume":"35","author":"Adam","year":"2015","journal-title":"Biosci. Rep."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119340_bib35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ijc.20719","article-title":"Aberrant expression of serine\/threonine kinase Pim-3 in hepatocellular carcinoma development and its role in the proliferation of human hepatoma cell lines","volume":"114","author":"Fujii","year":"2005","journal-title":"Int. J. Cancer"},{"issue":"21","key":"10.1016\/j.ejmech.2026.119340_bib36","doi-asserted-by":"crossref","first-page":"8373","DOI":"10.1021\/acs.jmedchem.5b01275","volume":"58","author":"Burger","year":"2015","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119340_bib37","first-page":"4079","article-title":"Downregulation of Pim-2 induces cell cycle arrest in the G(0)\/G(1) phase via the p53-non-dependent p21 signaling pathway","volume":"15","author":"Liu","year":"2018","journal-title":"Oncol. Lett."},{"issue":"13","key":"10.1016\/j.ejmech.2026.119340_bib38","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/0008-5472.CAN-08-0634","article-title":"Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels","volume":"68","author":"Morishita","year":"2008","journal-title":"Cancer Res."},{"issue":"35","key":"10.1016\/j.ejmech.2026.119340_bib39","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/onc.2008.123","article-title":"Pim kinase-dependent inhibition of c-Myc degradation","volume":"27","author":"Zhang","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.119340_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2121-7-1","article-title":"Pim kinases phosphorylate multiple sites on bad and promote 14-3-3 binding and dissociation from Bcl-XL","volume":"7","author":"Macdonald","year":"2006","journal-title":"BMC Cell Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119340_bib41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11864-023-01052-9","article-title":"New treatments for myelofibrosis","volume":"24","author":"Mesa","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib42","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41698-024-00638-2","article-title":"PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK\/STAT pathway mutations in T-ALL\/LBL","volume":"8","author":"Lahera","year":"2024","journal-title":"npj Precis. Oncol."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119340_bib43","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/s41375-018-0031-2","article-title":"High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK\/STAT activation or t(6;7)(p21;q34)\/TRB@-PIM1 rearrangement","volume":"32","author":"Starza","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119340_bib44","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41375-021-01464-2","article-title":"Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models","volume":"36","author":"Dutta","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119340_bib45","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1667\/RR2609.1","article-title":"PIM1-activated PRAS40 regulates radioresistance in non-small cell lung cancer cells through interplay with FOXO3a, 14-3-3 and protein phosphatases","volume":"176","author":"Kim","year":"2011","journal-title":"Radiat. Res."},{"issue":"15","key":"10.1016\/j.ejmech.2026.119340_bib46","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/0008-5472.CAN-12-4277","article-title":"eIF4B phosphorylation by pim kinases plays a critical role in cellular transformation by abl oncogenes","volume":"73","author":"Yang","year":"2013","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119340_bib47","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4161\/cbt.8.9.8210","article-title":"PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells","volume":"8","author":"Zhang","year":"2009","journal-title":"Cancer Biol. Ther."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119340_bib48","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-16-0305","article-title":"Systematic functional characterization of resistance to PI3K inhibition in breast cancer","volume":"6","author":"Le","year":"2016","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-020-0109-y","article-title":"PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer","volume":"5","author":"Luszczak","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119340_bib50","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.canlet.2018.12.015","article-title":"PIM1 kinase promotes cell proliferation, metastasis and tumor growth of lung adenocarcinoma by potentiating the c-MET signaling pathway","volume":"444","author":"Cao","year":"2019","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119340_bib51","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood-2013-01-481457","article-title":"Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation","volume":"122","author":"Lu","year":"2013","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ejmech.2026.119340_bib52","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1158\/0008-5472.CAN-05-4272","article-title":"Pim-3, a proto-oncogene with serine\/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines","volume":"66","author":"Li","year":"2006","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119340_bib53","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1349-7006.2007.00390.x","article-title":"Pim-3 with serine\/threonine kinase activity, is aberrantly expressed in human colon cancer cells and can prevent bad-mediated apoptosis","volume":"98","author":"Popivanova","year":"2007","journal-title":"Cancer Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119340_bib54","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.jpedsurg.2019.02.029","article-title":"The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival","volume":"54","author":"Stafman","year":"2019","journal-title":"J. Pediatr. Surg."},{"issue":"13","key":"10.1016\/j.ejmech.2026.119340_bib55","doi-asserted-by":"crossref","first-page":"10880","DOI":"10.18632\/oncotarget.3534","article-title":"PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma","volume":"6","author":"Leung","year":"2015","journal-title":"Oncotarget"},{"issue":"49","key":"10.1016\/j.ejmech.2026.119340_bib56","doi-asserted-by":"crossref","first-page":"35406","DOI":"10.1074\/jbc.M113.508226","article-title":"Proviral insertion in murine lymphomas 2 (PIM2) oncogene phosphorylates pyruvate kinase M2 (PKM2) and promotes glycolysis in cancer cells","volume":"288","author":"Yu","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119340_bib57","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/nm.4198","article-title":"PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer","volume":"22","author":"Bras\u00f3-Maristany","year":"2016","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119340_bib58","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1158\/1535-7163.MCT-13-0575-T","article-title":"PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2\/3) and CXCR4-mediated microenvironmental interactions (PIM1)","volume":"13","author":"Decker","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119340_bib59","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10585-022-10186-3","article-title":"PIM3 kinase promotes tumor metastasis in hepatoblastoma by upregulating cell surface expression of chemokine receptor cxcr4","volume":"39","author":"Marayati","year":"2022","journal-title":"Clin. Exp. Metastasis"},{"issue":"33","key":"10.1016\/j.ejmech.2026.119340_bib60","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1038\/s41388-024-03097-y","article-title":"Phosphorylation of USP27X by PIM2 promotes glycolysis and breast cancer progression via deubiquitylation of MYC","volume":"43","author":"Han","year":"2024","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib61","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00018-024-05487-7","article-title":"SPOP-mediated RIPK3 destabilization desensitizes LPS\/sMAC\/zVAD-induced necroptotic cell death","volume":"81","author":"Lee","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119340_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.73","article-title":"Pim2 is important for regulating DNA damage response in multiple myeloma cells","volume":"6","author":"Ramachandran","year":"2016","journal-title":"Blood Cancer J."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119340_bib63","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41419-024-07039-0","article-title":"PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3\u03b2 signaling pathway in EGFR-mutant non-small cell lung cancer","volume":"15","author":"Zhou","year":"2024","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119340_bib64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.yexcr.2016.02.018","article-title":"The PIM1 kinase promotes prostate cancer cell migration and adhesion via multiple signalling pathways","volume":"342","author":"Santio","year":"2016","journal-title":"Exp. Cell Res."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119340_bib65","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/cdd.2009.174","article-title":"Pim-1 controls NF-kappaB signalling by stabilizing RelA\/p65","volume":"17","author":"Nihira","year":"2010","journal-title":"Cell Death Differ."},{"issue":"30","key":"10.1016\/j.ejmech.2026.119340_bib66","doi-asserted-by":"crossref","first-page":"20635","DOI":"10.1074\/jbc.M709479200","article-title":"The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells","volume":"283","author":"Zemskova","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib67","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/s12967-023-04313-1","article-title":"Targeting macrophagic PIM-1 alleviates osteoarthritis by inhibiting NLRP3 inflammasome activation via suppressing mitochondrial ROS\/Cl(-) efflux signaling pathway","volume":"21","author":"Zhang","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119340_bib68","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2298865","article-title":"Inhibition of CEBPB attenuates lupus nephritis via regulating Pim-1 signaling","volume":"2022","author":"Wang","year":"2022","journal-title":"Mediat. Inflamm."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119340_bib69","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41419-020-2700-0","article-title":"PIM2 promotes hepatocellular carcinoma tumorigenesis and progression through activating NF-\u03baB signaling pathway","volume":"11","author":"Tang","year":"2020","journal-title":"Cell Death Dis."},{"issue":"18","key":"10.1016\/j.ejmech.2026.119340_bib70","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/0008-5472.CAN-21-3899","article-title":"PIM2 expression induced by proinflammatory macrophages suppresses immunotherapy efficacy in hepatocellular carcinoma","volume":"82","author":"Wang","year":"2022","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119340_bib71","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/molehr\/gax013","article-title":"Inhibition of PIM1 kinase attenuates inflammation-induced pro-labour mediators in human foetal membranes in vitro","volume":"23","author":"Lim","year":"2017","journal-title":"Mol. Hum. Reprod."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119340_bib72","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1158\/2326-6066.CIR-20-0433","article-title":"Targeting PIM1-Mediated metabolism in Myeloid suppressor cells to treat cancer","volume":"9","author":"Xin","year":"2021","journal-title":"Cancer Immunol. Res."},{"issue":"46","key":"10.1016\/j.ejmech.2026.119340_bib73","doi-asserted-by":"crossref","first-page":"17819","DOI":"10.1021\/acs.jafc.3c05371","article-title":"Bifidobacterium longum subsp. infantis B6MNI alleviates collagen-induced arthritis in rats via regulating 5-HIAA and Pim-1\/JAK\/STAT3 inflammation pathways","volume":"71","author":"Li","year":"2023","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2026.119340_bib74","first-page":"1137","volume":"vol. 9","author":"Su","year":"2026"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119340_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113469","article-title":"PIM kinases regulate early human Th17 cell differentiation","volume":"42","author":"Buchacher","year":"2023","journal-title":"Cell Rep."},{"issue":"33","key":"10.1016\/j.ejmech.2026.119340_bib76","doi-asserted-by":"crossref","first-page":"20211","DOI":"10.1074\/jbc.M115.638221","article-title":"Pim-2 kinase influences regulatory T cell function and stability by mediating Foxp3 protein N-terminal phosphorylation","volume":"290","author":"Deng","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"39","key":"10.1016\/j.ejmech.2026.119340_bib77","doi-asserted-by":"crossref","first-page":"26872","DOI":"10.1074\/jbc.M114.586651","article-title":"PIM1 kinase phosphorylates the human transcription factor FOXP3 at serine 422 to negatively regulate its activity under inflammation","volume":"289","author":"Li","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119340_bib78","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.clinre.2018.01.002","article-title":"Pim-1 inhibitor attenuates trinitrobenzene sulphonic acid induced colitis in the mice","volume":"42","author":"Shen","year":"2018","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"81","key":"10.1016\/j.ejmech.2026.119340_bib79","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn7993","article-title":"An XBP1s-PIM-2 positive feedback loop controls IL-15-mediated survival of natural killer cells","volume":"8","author":"Ma","year":"2023","journal-title":"Sci. Immunol."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119340_bib80","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/ncb1618","article-title":"PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation","volume":"9","author":"Zippo","year":"2007","journal-title":"Nat. Cell Biol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119340_bib81","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2024.04.017","article-title":"PIM1-HDAC2 axis modulates intestinal homeostasis through epigenetic modification","volume":"14","author":"Yang","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"7","key":"10.1016\/j.ejmech.2026.119340_bib82","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/onc.2011.278","article-title":"The proto-oncogene Pim-1 is a target of miR-33a","volume":"31","author":"Thomas","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.119340_bib83","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/1476-4598-13-240","article-title":"Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer","volume":"13","author":"Pang","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119340_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2020.104438","article-title":"MiR-195 suppression alleviates apoptosis and oxidative stress in CCl4-induced ALI in mice by targeting Pim-1","volume":"115","author":"Yang","year":"2020","journal-title":"Exp. Mol. Pathol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119340_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110280","article-title":"Pim-1 kinase protects the liver from ischemia reperfusion injury by regulating dynamics-related protein 1","volume":"27","author":"Sun","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.ejmech.2026.119340_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106565","article-title":"Long non-coding RNA LINC01003 suppresses the development of multiple myeloma by targeting miR-33a-5p\/PIM1 axis","volume":"106","author":"Wu","year":"2021","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2026.119340_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.139152","article-title":"SND1-SMARCA5 interaction strengthened by PIM promotes the proliferation, metastasis, and chemoresistance of esophageal squamous cell carcinoma","volume":"291","author":"Yan","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib88","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12943-023-01762-6","article-title":"CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma","volume":"22","author":"Thieme","year":"2023","journal-title":"Mol. Cancer"},{"issue":"6666","key":"10.1016\/j.ejmech.2026.119340_bib89","doi-asserted-by":"crossref","DOI":"10.1126\/science.adg2253","article-title":"PIM1 controls GBP1 activity to limit self-damage and to guard against pathogen infection","volume":"382","author":"Fisch","year":"2023","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119340_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1500221","article-title":"Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia","volume":"1","author":"Green","year":"2015","journal-title":"Sci. Adv."},{"issue":"17","key":"10.1016\/j.ejmech.2026.119340_bib152","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1038\/onc.2010.10","article-title":"Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma","volume":"29","author":"Wang","year":"2010","journal-title":"Oncogene"},{"issue":"33","key":"10.1016\/j.ejmech.2026.119340_bib114","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41388-024-03100-6","article-title":"PIM1\/NF-\u03baB\/CCL2 blockade enhances anti-PD-1 therapy response by modulating macrophage infiltration and polarization in tumor microenvironment of NSCLC","volume":"43","author":"Chen","year":"2024","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119340_bib95","doi-asserted-by":"crossref","first-page":"385","DOI":"10.17219\/acem\/90771","article-title":"Expression of the PIM2 gene is associated with more aggressive clinical course in patients with chronic lymphocytic leukemia","volume":"28","author":"Kapelko-S\u0142owik","year":"2019","journal-title":"Adv. Clin. Exp. Med."},{"issue":"18","key":"10.1016\/j.ejmech.2026.119340_bib133","doi-asserted-by":"crossref","first-page":"22412","DOI":"10.18632\/aging.203547","article-title":"Pim-2 kinase inhibits inflammation by suppressing the mTORC1 pathway in atherosclerosis","volume":"13","author":"Liao","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"20","key":"10.1016\/j.ejmech.2026.119340_bib134","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1182\/blood-2011-03-344374","article-title":"PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma","volume":"118","author":"G\u00f3mez-Abad","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119340_bib135","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1182\/blood-2017-01-760702","article-title":"Expression of PIM kinases in reed-sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma","volume":"130","author":"Szyd\u0142owski","year":"2017","journal-title":"Blood"},{"issue":"45","key":"10.1016\/j.ejmech.2026.119340_bib132","doi-asserted-by":"crossref","first-page":"5997","DOI":"10.1038\/s41388-018-0386-x","article-title":"PIM2-mediated phosphorylation of hexokinase 2 is critical for tumor growth and paclitaxel resistance in breast cancer","volume":"37","author":"Yang","year":"2018","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119340_bib153","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1158\/2767-9764.CRC-23-0379","article-title":"Pim kinase inhibitors increase gilteritinib cytotoxicity in FLT3-ITD acute myeloid leukemia through GSK-3\u03b2 activation and c-Myc and Mcl-1 proteasomal degradation","volume":"4","author":"Lee","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119340_bib131","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/leu.2011.60","article-title":"The serine\/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells","volume":"25","author":"Asano","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib140","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/leu.2014.147","article-title":"Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma","volume":"29","author":"Hiasa","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119340_bib143","first-page":"348","article-title":"Serine threonine kinase Pim-3 regulates STAT3 pathway to inhibit proliferation of human liver cancers","volume":"7","author":"Wang","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119340_bib144","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.tranon.2018.10.008","article-title":"Targeting PIM kinases affects maintenance of CD133 tumor cell population in hepatoblastoma","volume":"12","author":"Stafman","year":"2019","journal-title":"Transl. Oncol."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119340_bib146","doi-asserted-by":"crossref","first-page":"579","DOI":"10.21037\/atm-22-1561","article-title":"Long non-coding RNA (FALEC) promotes malignant behaviors of gastric cancer cells by regulating miR-203b\/PIM3 axis","volume":"10","author":"Dong","year":"2022","journal-title":"Ann. Transl. Med."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119340_bib151","first-page":"4427","article-title":"Pim-3 alleviates lipopolysaccharide-stimulated AR42J pancreatic acinar cell injury via improving the inflammatory microenvironment","volume":"18","author":"Jian","year":"2019","journal-title":"Exp. Ther. Med."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119340_bib142","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1021\/acs.jproteome.9b00821","article-title":"Proto-oncogene serine\/threonine kinase PIM3 promotes cell migration via modulating rho GTPase signaling","volume":"19","author":"Dang","year":"2020","journal-title":"J. Proteome Res."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119340_bib154","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.7150\/jca.18628","article-title":"Pim-3 regulates stemness of pancreatic cancer cells via activating STAT3 signaling pathway","volume":"8","author":"Li","year":"2017","journal-title":"J. Cancer"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119340_bib150","doi-asserted-by":"crossref","first-page":"448","DOI":"10.18632\/oncotarget.283","article-title":"The direct Myc target Pim3 cooperates with other pim kinases in supporting viability of Myc-induced B-cell lymphomas","volume":"2","author":"Forshell","year":"2011","journal-title":"Oncotarget"},{"issue":"15","key":"10.1016\/j.ejmech.2026.119340_bib91","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-Cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib92","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-023-01358-y","article-title":"Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma","volume":"8","author":"Shen","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"11","key":"10.1016\/j.ejmech.2026.119340_bib93","doi-asserted-by":"crossref","first-page":"7395","DOI":"10.1111\/jcmm.14601","article-title":"Long non-coding RNA SNHG16 promotes proliferation and inhibits apoptosis of diffuse large B-cell lymphoma cells by targeting miR-497-5p\/PIM1 axis","volume":"23","author":"Zhu","year":"2019","journal-title":"J. Cell Mol. Med."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119340_bib94","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1111\/jcmm.13632","article-title":"Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration","volume":"22","author":"Bia\u0142opiotrowicz","year":"2018","journal-title":"J. Cell Mol. Med."},{"issue":"29","key":"10.1016\/j.ejmech.2026.119340_bib96","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.18632\/oncotarget.26876","article-title":"PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells","volume":"10","author":"Cervantes-Gomez","year":"2019","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.ejmech.2026.119340_bib97","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/blood.2019003880","article-title":"Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma","volume":"135","author":"Smedt","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ejmech.2026.119340_bib98","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/pathogens9070543","article-title":"Mechanisms of oncogenesis by HTLV-1 tax","volume":"9","author":"Mohanty","year":"2020","journal-title":"Pathogens"},{"issue":"20","key":"10.1016\/j.ejmech.2026.119340_bib99","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1182\/blood-2015-11-685032","article-title":"Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia","volume":"127","author":"Bellon","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.ejmech.2026.119340_bib100","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7445","article-title":"NUP98-BPTF promotes oncogenic transformation through PIM1 upregulation","volume":"13","author":"Noura","year":"2024","journal-title":"Cancer Med."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119340_bib101","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-13-2062","article-title":"Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers","volume":"20","author":"Garcia","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119340_bib102","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3390\/pharmaceutics15071991","article-title":"Synthesis and anticancer activity of novel dual inhibitors of human protein kinases CK2 and PIM-1","volume":"15","author":"Wi\u0144ska","year":"2023","journal-title":"Pharmaceutics"},{"issue":"18","key":"10.1016\/j.ejmech.2026.119340_bib103","doi-asserted-by":"crossref","first-page":"30199","DOI":"10.18632\/oncotarget.16320","article-title":"Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset","volume":"8","author":"Padi","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119340_bib104","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1365-2141.2006.06225.x","article-title":"Constitutively activated FLT3 phosphorylates BAD partially through pim-1","volume":"134","author":"Kim","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib105","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/acs.jmedchem.1c02019","article-title":"Discovery of dual CDK6\/PIM1 inhibitors with a novel structure, high potency, and favorable druggability for the treatment of acute myeloid leukemia","volume":"65","author":"Yuan","year":"2022","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2026.119340_bib106","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood-2015-11-683581","article-title":"Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6","volume":"127","author":"Uras","year":"2016","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.ejmech.2026.119340_bib107","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70017","article-title":"Construction and validation of a SASP-related prognostic signature in patients with acute myeloid leukaemia","volume":"28","author":"Li","year":"2024","journal-title":"J. Cell Mol. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib108","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1158\/1078-0432.CCR-16-0230","article-title":"The novel Pan-PIM kinase inhibitor, PIM447, displays dual antimyeloma and bone-protective effects, and potently synergizes with current standards of care","volume":"23","author":"Pa\u00edno","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.ejmech.2026.119340_bib109","doi-asserted-by":"crossref","first-page":"7460","DOI":"10.4049\/jimmunol.1000885","article-title":"Pim-1 regulates RANKL-Induced osteoclastogenesis via NF-\u03baB activation and NFATc1 induction","volume":"185","author":"Kim","year":"2010","journal-title":"J. Immunol."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2026.119340_bib110","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood-2025-2018","article-title":"Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed\/refractory myelofibrosis in the ongoing global phase I\/II study","volume":"146","author":"Rein","year":"2025","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119340_bib111","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.3390\/ijms24065464","article-title":"Neoprzewaquinone A inhibits breast cancer cell migration and promotes smooth muscle relaxation by targeting PIM1 to block ROCK2\/STAT3 pathway","volume":"24","author":"Zhao","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119340_bib112","doi-asserted-by":"crossref","first-page":"366","DOI":"10.21037\/atm.2020.02.43","article-title":"PIM1 inhibitor synergizes the anti-tumor effect of osimertinib via STAT3 dephosphorylation in EGFR-mutant non-small cell lung cancer","volume":"8","author":"Sun","year":"2020","journal-title":"Ann. Transl. Med."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119340_bib113","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3390\/cancers13092139","article-title":"Co-Targeting PIM kinase and PI3K\/mTOR in NSCLC","volume":"13","author":"Moore","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119340_bib115","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1038\/s41388-020-1168-9","article-title":"PIM kinases alter mitochondrial dynamics and chemosensitivity in lung cancer","volume":"39","author":"Chauhan","year":"2020","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.ejmech.2026.119340_bib116","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1002\/cam4.3893","article-title":"Expression and ERG regulation of PIM kinases in prostate cancer","volume":"10","author":"Eerola","year":"2021","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib117","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/carcin\/bgy126","article-title":"Kinase PIM1 promotes prostate cancer cell growth via c-Myc-RPS7-driven ribosomal stress","volume":"40","author":"Zhang","year":"2019","journal-title":"Carcinogenesis"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119340_bib118","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202208136","article-title":"PIM1 phosphorylates ABI2 to enhance actin dynamics and promote tumor invasion","volume":"222","author":"Jensen","year":"2023","journal-title":"J. Cell Biol."},{"issue":"34","key":"10.1016\/j.ejmech.2026.119340_bib119","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1038\/onc.2012.412","article-title":"Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer","volume":"32","author":"Ha","year":"2013","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.ejmech.2026.119340_bib120","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1158\/2326-6066.CIR-24-0591","article-title":"Inhibition of PIM kinase in tumor-associated macrophages suppresses inflammasome activation and sensitizes prostate cancer to immunotherapy","volume":"13","author":"Clements","year":"2025","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib121","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jcmgh.2022.09.014","article-title":"PIM1-Induced cytoplasmic expression of RBMY mediates hepatocellular carcinoma metastasis","volume":"15","author":"Chua","year":"2023","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.ejmech.2026.119340_bib122","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.4251\/wjgo.v15.i8.1400","article-title":"Physcion increases the sensitivity of hepatocellular carcinoma to sorafenib through miRNA-370\/PIM1 axis-regulated glycolysis","volume":"15","author":"Pan","year":"2023","journal-title":"World J. Gastrointest. Oncol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119340_bib123","first-page":"1254","article-title":"miRNA-370 acts as a tumor suppressor via the downregulation of PIM1 in hepatocellular carcinoma","volume":"21","author":"Pan","year":"2017","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.119340_bib124","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.2147\/DDDT.S327270","article-title":"Ventilagolin suppresses migration, invasion and epithelial-mesenchymal transition of hepatocellular carcinoma cells by downregulating Pim-1","volume":"15","author":"Liu","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119340_bib125","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/neuonc\/nou216","article-title":"Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival","volume":"17","author":"Herzog","year":"2015","journal-title":"Neuro Oncol."},{"issue":"20","key":"10.1016\/j.ejmech.2026.119340_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011126","article-title":"PIM1 inhibition affects glioblastoma stem cell behavior and kills glioblastoma stem-like cells","volume":"22","author":"Seifert","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119340_bib127","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bbamcr.2018.10.017","article-title":"Inhibition of PIM1 blocks the autophagic flux to sensitize glioblastoma cells to ABT-737-induced apoptosis","volume":"1866","author":"Remy","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119340_bib128","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/carcin\/bgr007","article-title":"The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells","volume":"32","author":"Xu","year":"2011","journal-title":"Carcinogenesis"},{"issue":"19","key":"10.1016\/j.ejmech.2026.119340_bib129","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1038\/onc.2015.325","article-title":"The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells","volume":"35","author":"Blanco","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib130","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13046-016-0406-z","article-title":"PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value","volume":"35","author":"Xu","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119340_bib136","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12943-015-0477-z","article-title":"Loss of PIM2 enhances the anti-proliferative effect of the pan-PIM kinase inhibitor AZD1208 in Non-Hodgkin lymphomas","volume":"14","author":"Kreuz","year":"2015","journal-title":"Mol. Cancer"},{"issue":"15","key":"10.1016\/j.ejmech.2026.119340_bib137","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood.2021014011","article-title":"PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma","volume":"139","author":"Haas","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib138","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41467-024-55572-5","article-title":"PIM2 inhibition promotes MCL1 dependency in plasma cells involving integrated stress response-driven NOXA expression","volume":"16","author":"Haas","year":"2025","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.ejmech.2026.119340_bib139","doi-asserted-by":"crossref","first-page":"4441","DOI":"10.3390\/cancers13174441","article-title":"Myeloma-bone interaction: a vicious cycle via TAK1-PIM2 signaling","volume":"13","author":"Harada","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ejmech.2026.119340_bib141","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bjh.14388","article-title":"Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma","volume":"180","author":"Teramachi","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"32","key":"10.1016\/j.ejmech.2026.119340_bib145","doi-asserted-by":"crossref","first-page":"22665","DOI":"10.18632\/oncotarget.25205","article-title":"Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma","volume":"9","author":"Stafman","year":"2018","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.ejmech.2026.119340_bib147","doi-asserted-by":"crossref","first-page":"14440","DOI":"10.18632\/oncotarget.3885","article-title":"MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine","volume":"6","author":"Liang","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib148","first-page":"42","article-title":"Knockdown of Pim-3 suppresses the tumorigenicity of glioblastoma by regulating cell cycle and apoptosis","volume":"61","author":"Quan","year":"2015","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"3","key":"10.1016\/j.ejmech.2026.119340_bib149","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/15384047.2017.1414756","article-title":"Pim-3 enhances melanoma cell migration and invasion by promoting STAT3 phosphorylation","volume":"19","author":"Liu","year":"2018","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib155","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/rheumatology\/key261","article-title":"PIM-1 kinase is a novel regulator of proinflammatory cytokine-mediated responses in rheumatoid arthritis fibroblast-like synoviocytes","volume":"58","author":"Ha","year":"2019","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119340_bib156","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cellimm.2011.10.011","article-title":"The role of PIM kinases in human and mouse CD4+ T cell activation and inflammatory bowel disease","volume":"272","author":"Jackson","year":"2012","journal-title":"Cell. Immunol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.119340_bib157","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.neo.2014.05.004","article-title":"A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas","volume":"16","author":"Foulks","year":"2014","journal-title":"Neoplasia"},{"issue":"17","key":"10.1016\/j.ejmech.2026.119340_bib158","doi-asserted-by":"crossref","first-page":"9440","DOI":"10.3390\/ijms22179440","article-title":"The second-generation PIM kinase inhibitor TP-3654 resensitizes ABCG2-Overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs","volume":"22","author":"Wu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119340_bib159","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejmech.2019.03.050","article-title":"PIM kinase inhibitors: structural and pharmacological perspectives","volume":"172","author":"Asati","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"Suppl 7","key":"10.1016\/j.ejmech.2026.119340_bib169","doi-asserted-by":"crossref","first-page":"CT116","DOI":"10.1158\/1538-7445.AM2024-CT116","article-title":"Preclinical antitumor activity and first-in-human phase I study of NB004\/GDC-0570, a novel pan-PIM kinase inhibitor, in patients with advanced solid tumors","volume":"84","author":"Fu","year":"2024","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.ejmech.2026.119340_bib160","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1016\/j.bmcl.2012.05.098","article-title":"Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases","volume":"22","author":"Dakin","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119340_bib161","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2013-04-495366","article-title":"AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia","volume":"123","author":"Keeton","year":"2014","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119340_bib162","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.3109\/10428194.2016.1166489","article-title":"Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia","volume":"57","author":"Chen","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119340_bib163","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s12185-021-03096-9","article-title":"A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and\/or refractory multiple myeloma","volume":"113","author":"Iida","year":"2021","journal-title":"Int. J. Hematol."},{"issue":"10","key":"10.1016\/j.ejmech.2026.119340_bib164","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.3390\/cancers12102743","article-title":"Protein translation inhibition is involved in the activity of the Pan-PIM kinase inhibitor PIM447 in combination with pomalidomide-dexamethasone in multiple myeloma","volume":"12","author":"Pa\u00edno","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119340_bib165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199108","article-title":"Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies","volume":"13","author":"Koblish","year":"2018","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.ejmech.2026.119340_bib166","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.70235","article-title":"The dual PIM\/FLT3 inhibitor MEN1703 combines synergistically with gilteritinib in FLT3-ITD-Mutant acute Myeloid leukaemia","volume":"28","author":"Zicari","year":"2024","journal-title":"J. Cell Mol. Med."},{"issue":"23","key":"10.1016\/j.ejmech.2026.119340_bib167","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.1158\/0008-5472.CAN-21-1023","article-title":"Inhibition of PIM kinases in DLBCL Targets MYC transcriptional program and augments the efficacy of Anti-CD20 antibodies","volume":"81","author":"Szyd\u0142owski","year":"2021","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119340_bib168","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1021\/acs.jmedchem.8b01857","article-title":"Optimization of pan-pim kinase activity and oral bioavailability leading to diaminopyrazole (GDC-0339) for the treatment of multiple myeloma","volume":"62","author":"Wang","year":"2019","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119340_bib170","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1161\/ATVBAHA.119.313763","article-title":"PIM1 (moloney murine leukemia provirus integration site) inhibition decreases the nonhomologous end-joining DNA damage repair signaling pathway in pulmonary hypertension","volume":"40","author":"Lampron","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119340_bib171","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1021\/ml200259q","article-title":"Discovery of CX-6258. A potent, selective, and orally efficacious pan-Pim kinases inhibitor","volume":"3","author":"Haddach","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119340_bib172","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.bmcl.2006.12.086","article-title":"Identification and structure-activity relationships of substituted pyridones as inhibitors of Pim-1 kinase","volume":"17","author":"Cheney","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119340_bib173","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3109\/14756366.2016.1158711","article-title":"Synthesis of new thieno[2,3-b]pyridine derivatives as pim-1 inhibitors","volume":"31","author":"Naguib","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib174","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/14756366.2016.1261130","article-title":"Synthesis of new pyridothienopyrimidinone derivatives as Pim-1 inhibitors","volume":"32","author":"Naguib","year":"2017","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"41","key":"10.1016\/j.ejmech.2026.119340_bib175","doi-asserted-by":"crossref","first-page":"30346","DOI":"10.1039\/D4RA04036H","article-title":"Design, synthesis, biological evaluation, and docking studies of novel triazolo[4,3-b]pyridazine derivatives as dual c-Met\/Pim-1 potential inhibitors with antitumor activity","volume":"14","author":"Mahmoud","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.119340_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107880","article-title":"Synthesis and evaluation of anticancer activity of new 4,5,6,7-tetrabromo-1H-benzimidazole derivatives","volume":"153","author":"\u0141ukowska-Chojnacka","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119340_bib177","doi-asserted-by":"crossref","first-page":"867","DOI":"10.3390\/molecules26040867","article-title":"New quinoxaline derivatives as dual Pim-1\/2 kinase inhibitors: design, synthesis and biological evaluation","volume":"26","author":"Oyallon","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119340_bib178","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128874","article-title":"Design, synthesis, and bioactivity evaluation of macrocyclic benzo[b]pyrido[4,3-e][1,4]oxazine derivatives as novel Pim-1 kinase inhibitors","volume":"72","author":"Xu","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"10.1016\/j.ejmech.2026.119340_bib179","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3892\/ijo.2022.5404","article-title":"Targeting PIM2 by JP11646 results in significant antitumor effects in solid tumors","volume":"61","author":"Katsuta","year":"2022","journal-title":"Int. J. Oncol."},{"issue":"14","key":"10.1016\/j.ejmech.2026.119340_bib180","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.3390\/ijms21145138","article-title":"Anti-Inflammatory effects of the novel PIM kinase inhibitor KMU-470 in RAW 264.7 cells through the TLR4-NF-\u03baB-NLRP3 pathway","volume":"21","author":"Baek","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"22","key":"10.1016\/j.ejmech.2026.119340_bib181","doi-asserted-by":"crossref","first-page":"19351","DOI":"10.1021\/acsomega.2c08304","article-title":"Cyanopyridinone- and cyanopyridine-based cancer cell Pim-1 inhibitors: design, synthesis, radiolabeling, biodistribution, and molecular modeling simulation","volume":"8","author":"Mansour","year":"2023","journal-title":"ACS Omega"},{"issue":"11","key":"10.1016\/j.ejmech.2026.119340_bib182","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/chir.23501","article-title":"Stereoselective synthesis of 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as PIM kinase inhibitors inspired from marine alkaloids","volume":"34","author":"Casuscelli","year":"2022","journal-title":"Chirality"},{"issue":"8","key":"10.1016\/j.ejmech.2026.119340_bib183","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/leu.2016.379","article-title":"Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma","volume":"31","author":"Nair","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.ejmech.2026.119340_bib184","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/ejh.14420","article-title":"Dual targeting of pim and PI3 kinases in mature T-Cell lymphoma","volume":"115","author":"Lohrberg","year":"2025","journal-title":"Eur. J. Haematol."},{"issue":"25","key":"10.1016\/j.ejmech.2026.119340_bib185","doi-asserted-by":"crossref","first-page":"37407","DOI":"10.18632\/oncotarget.9822","article-title":"Intrinsic resistance to PIM kinase inhibition in AML through p38\u03b1-mediated feedback activation of mTOR signaling","volume":"7","author":"Brunen","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.ejmech.2026.119340_bib186","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1158\/1535-7163.MCT-20-0160","article-title":"PIM kinase inhibitors block the growth of primary T-cell acute lymphoblastic leukemia: resistance pathways identified by network modeling analysis","volume":"19","author":"Lim","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.119340_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.110794","article-title":"PIM kinase inhibition counters resistance to radiotherapy and chemotherapy in human prostate cancer","volume":"206","author":"Rajkumar-Calkins","year":"2025","journal-title":"Radiother. Oncol."},{"issue":"15","key":"10.1016\/j.ejmech.2026.119340_bib188","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/bloodadvances.2022008144","article-title":"Deep PIM kinase substrate profiling reveals new rational cotherapeutic strategies for acute myeloid leukemia","volume":"8","author":"Joglekar","year":"2024","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.ejmech.2026.119340_bib189","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.18632\/oncotarget.7164","article-title":"eIF4B is a convergent target and critical effector of oncogenic pim and PI3K\/Akt\/mTOR signaling pathways in abl transformants","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.ejmech.2026.119340_bib190","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ejmech.2026.119340_bib191","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119340_bib192","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.leukres.2011.07.011","article-title":"A potential therapeutic target for FLT3-ITD AML: PIM1 kinase","volume":"36","author":"Fathi","year":"2012","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119340_bib193","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12185-023-03705-9","article-title":"Acute accumulation of PIM2 and NRF2 and recovery of \u03b25 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors","volume":"119","author":"Sogabe","year":"2024","journal-title":"Int. J. Hematol."},{"issue":"Suppl 1","key":"10.1016\/j.ejmech.2026.119340_bib198","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2024-201572","article-title":"PIM447, a Pan-PIM kinase inhibitor, in combination with venetoclax exerts a potent anti-tumor activity in the bone marrow niche","volume":"144","author":"Roversi","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119340_bib197","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70055","article-title":"Targeting of PIM kinases shows single agent efficacy and synergizes with BCL2 inhibitors in diffuse large B cell lymphoma of the ABC subtype","volume":"43","author":"Tarantelli","year":"2025","journal-title":"Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.ejmech.2026.119340_bib194","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.jpedsurg.2024.03.014","article-title":"PIM kinase inhibition sensitizes neuroblastoma to doxorubicin","volume":"59","author":"Julson","year":"2024","journal-title":"J. Pediatr. Surg."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119340_bib195","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.chembiol.2021.08.011","article-title":"Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-Overexpressing triple-negative breast cancer","volume":"29","author":"Kunder","year":"2022","journal-title":"Cell Chem. Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119340_bib196","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/1078-0432.CCR-18-0706","article-title":"Targeting PIM kinase with PD1 inhibition improves immunotherapeutic antitumor T-cell response","volume":"25","author":"Chatterjee","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119340_bib199","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2024.100996","article-title":"Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: synergistic effect and metabolic mechanisms","volume":"52","author":"Xu","year":"2024","journal-title":"Neoplasia"},{"issue":"19","key":"10.1016\/j.ejmech.2026.119340_bib200","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood-2009-03-212852","article-title":"Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells","volume":"114","author":"Chen","year":"2009","journal-title":"Blood"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:25:30Z","timestamp":1792643130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426007853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":200,"alternative-id":["S0223523426007853"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119340","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting PIM kinases in cancer and inflammatory disorders: From mechanisms to clinical translation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119340","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119340"}}